Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates ...

The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

IROS and Halia Therapeutics’ clinical trial will explore a promising new therapy for obesity, specifically designed to ...

In response to a recent article about an interesting biotechnology stock, a reader recently asked me how to handle the ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

A Race Against Blindness, an Arizona-based nonprofit organization, has awarded a $1 million grant to fund research and clinical trials focused on Bardet-Biedl Syndrome 1 (BBS1), a rare genetic ...

Obudanersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Angelman Syndrome.

Dofetilide is under clinical development by Hyloris Pharmaceuticals and currently in Phase I for Atrial Flutter.

The "AI in Clinical Trials Market by Function, Phase, Indication, Tool, End-User & Region - Global Forecast to 2030" report ...

A Race Against Blindness, an Arizona-based nonprofit organization, has awarded a $1 million grant to fund research and clinical trials focused on ...